 M-pagliflasein, a sodium-glucose-cotransporter, 2-inhibitor, SGLT2i, has been shown to reduce lipid accumulation and improve kidney function in experimental Alport syndrome, AS. This study demonstrates that SGLT2i can be used to treat AS by reducing podocyte lipotoxicity and improving kidney function. This article was authored by Meng Yuan Ji, Judith Molina, Jindu Kim, and others.